Showing results (71-80 of 149) with videos related to

Sort By:
Pageof 15
Cancers|March 4, 2020
Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian CancerStefanie Aust, Richard Schwameis, Tamara Gagic, et al.
Leukemia & Lymphoma|September 25, 2014
The potential evasion of immune surveillance in mucosa associated lymphoid tissue lymphoma by DcR2-mediated up-regulation of nuclear factor-κBMariam Anees, Peter Horak, Ana-Iris Schiefer, et al.
Scientific Reports|November 24, 2019
Follistatin impacts Tumor Angiogenesis and Outcome in Thymic Epithelial TumorsStefan Janik, Christine Bekos, Philipp Hacker, et al.
Scientific Reports|December 11, 2019
Clinical prognostic scores for patients with thymic epithelial tumorsCecilia Veraar, Stefan Janik, Jürgen Thanner, et al.
Wiener Klinische Wochenschrift|November 4, 2017
Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfallsChristiane Thallinger, Thorsten Füreder, Matthias Preusser, et al.
European Journal of Haematology|March 13, 2014
Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemiaVeronika Buxhofer-Ausch, Damla Olcaydu, Bettina Gisslinger, et al.
Oncotarget|May 19, 2018
Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcomeStefan Janik, Thomas Raunegger, Philipp Hacker, et al.
Therapeutic Advances in Medical Oncology|September 14, 2020
Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRCDaniela Bianconi, Merima Herac, Florian Posch, et al.
Annals of Hematology|February 18, 2011
Prevalence and clinical impact of autoimmune diseases and chronic infections in malignant lymphomas at diagnosisKatrina Vanura, Florentin Späth, Andreas Gleiss, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 5, 2011
Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasmsGregor Hoermann, Sabine Cerny-Reiterer, Harald Herrmann, et al.
Pageof 15